RxDoctor Payments Data

Jaima Woodiwiss, MD

Family Medicine · Riverview, FLNPI 1902822323

Payments from drug & device makers

$798in general payments, 2019–2025

Across 43 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$175
  • GSK$151
  • Johnson & Johnson$144
  • AbbVie$143
  • Novo Nordisk$80
  • Nevro Corp.$64
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott12$175
GSK3$151
Johnson & Johnson10$144
AbbVie9$143
Novo Nordisk5$80
Nevro Corp.1$64
Amgen(2 entities)2$30
Boston Scientific1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$205,349
Medicare patients
370
Services billed
3,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$63,411
MounjaroTirzepatide53$60,808
EliquisApixaban56$55,253
JanuviaSitagliptin Phosphate31$40,794
JardianceEmpagliflozin18$29,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,904
XareltoRivaroxaban15$18,793
LinzessLinaclotide18$15,230
Breo ElliptaFluticasone/Vilanterol27$15,195
RybelsusSemaglutide14$11,426
Tresiba Flextouch U-100Insulin Degludec12$10,419
TradjentaLinagliptin11$8,024
SynthroidLevothyroxine Sodium62$5,778
Advair HfaFluticasone Propion/Salmeterol13$5,621
ShingrixVaricella-Zoster Ge/As01b/Pf22$4,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$80$74,83767 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy$151$45,30485 claims
AbbVieLinzess, Synthroid$143$21,00880 claims
Johnson & JohnsonXarelto$144$18,79315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →